Andere talen Senti Biosciences, Inc.

Aandelen

SNTI

US81726A1007

slotkoers Nasdaq Andere beurzen 00:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,38 ^USD	+5,56%		+36,35%	-42,42%

30/04	Senti Biosciences, Inc. Kondigt de publicatie aan van SENTI-202 preklinische gegevens die het potentieel aantonen van logisch gestuurde CAR-NK celtherapie voor de behandeling van acute myeloïde leukemie (AML)	CI
26/04	Senti Biosciences, Inc. kondigt aan dat Deborah Knobelman met ingang van 3 mei 2024 ontslag neemt als penningmeester en hoofd bedrijfsontwikkeling	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	30/04
Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	30/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13/11
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	06/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Senti Biosciences, Inc.

Aandelen

SNTI

US81726A1007

Andere talen

Filters